Pharmacotherapeutic perspectives on nutraceuticals in the treatment of MASLD and MASH
Saved in:
| Main Authors: | Ali H. Eid, Maha Khachab, Firas Kobeissy, Amirhossein Sahebkar |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-05-01
|
| Series: | Therapeutic Advances in Chronic Disease |
| Online Access: | https://doi.org/10.1177/20406223251339388 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluation of the prevalence of MASLD, MASH and liver fibrosis in a Dutch bariatric cohort.
by: Willy Theel, et al.
Published: (2025-01-01) -
Evaluation of the prevalence of MASLD, MASH and liver fibrosis in a Dutch bariatric cohort
by: Willy Theel, et al.
Published: (2025-01-01) -
Meta-analysis of shotgun sequencing of gut microbiota in obese children with MASLD or MASH
by: Thomas Zöggeler, et al.
Published: (2025-12-01) -
Lactobacillus rhamnosus GG attenuates MASLD/MASH progression by modulating gut microbiota and metabolic pathways
by: Shi-Long Wang, et al.
Published: (2025-07-01) -
Japanese encephalitis in north-east, India: Pharmacotherapeutic perspectives
by: Moksood Ahmed Laskar, et al.
Published: (2025-06-01)